199 related articles for article (PubMed ID: 32729113)
1. Reciprocal ATP5L-KMT2A gene fusion in a paediatric B lymphoblastic leukaemia/lymphoma (B-ALL) patient.
Gestrich CK; Sadri N; Sinno MG; Pateva I; Meyerson HJ
Br J Haematol; 2020 Oct; 191(2):e61-e64. PubMed ID: 32729113
[No Abstract] [Full Text] [Related]
2. Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis.
Haddox CL; Mangaonkar AA; Chen D; Shi M; He R; Oliveira JL; Litzow MR; Al-Kali A; Hogan WJ; Elliott MA
Blood Cancer J; 2017 Sep; 7(9):e607. PubMed ID: 29016570
[No Abstract] [Full Text] [Related]
3. Rearrangements of ATP5L-KMT2A in acute lymphoblastic leukaemia.
Ferrari A; Ghelli Luserna Di Rora A; Domizio C; Papayannidis C; Simonetti G; Maria Hernández-Rivas J; Rondoni M; Giglio F; Abruzzese E; Imovilli A; Iacobucci I; Calistri D; Martinelli G
Br J Haematol; 2021 Mar; 192(6):e139-e144. PubMed ID: 33314053
[No Abstract] [Full Text] [Related]
4. A novel KMT2A-ACTN2 fusion in infant B-cell acute lymphoblastic leukemia.
Yoshida M; Nakabayashi K; Ogata-Kawata H; Osumi T; Tsujimoto SI; Shirai R; Yoshida K; Okamura K; Matsumoto K; Kiyokawa N; Tomizawa D; Hata K; Kato M
Pediatr Blood Cancer; 2019 Aug; 66(8):e27821. PubMed ID: 31115144
[No Abstract] [Full Text] [Related]
5. First report of t(5;11) KMT2A-MAML1 fusion in de novo infant acute lymphoblastic leukemia.
Tandon S; Shago M; Davidson S; Kanwar N; Fuligni F; Shlien A; Whitlock J; Villani A; Abla O
Cancer Genet; 2020 Oct; 248-249():31-33. PubMed ID: 32992102
[TBL] [Abstract][Full Text] [Related]
6. Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants.
Fazio G; Bardini M; De Lorenzo P; Grioni A; Quadri M; Pedace L; Corral Abascal L; Palamini S; Palmi C; Buldini B; Vinti L; Parasole R; Barisone E; Zecca M; Favre C; Locatelli F; Conter V; Rizzari C; Valsecchi MG; Biondi A; Cazzaniga G
Blood; 2021 Apr; 137(14):1980-1984. PubMed ID: 33512459
[No Abstract] [Full Text] [Related]
7. Inv(11)(q21q23); KMT2A-MAML2, a Recurrent Genetic Abnormality in T-Cell Therapy-related Acute Lymphoblastic Leukemia.
Mariani RA; Silva M; Caparelli E; Jennings LJ; Yap KL; Leuer KM; Weinstein J; Gong S
J Pediatr Hematol Oncol; 2020 May; 42(4):e258-e261. PubMed ID: 31343482
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic haematopoietic stem cell transplantation for infant acute lymphoblastic leukaemia with KMT2A (MLL) rearrangements: a retrospective study from the paediatric acute lymphoblastic leukaemia working group of the Japan Society for Haematopoietic Cell Transplantation.
Kato M; Hasegawa D; Koh K; Kato K; Takita J; Inagaki J; Yabe H; Goto H; Adachi S; Hayakawa A; Takeshita Y; Sawada A; Atsuta Y; Kato K
Br J Haematol; 2015 Feb; 168(4):564-70. PubMed ID: 25302748
[TBL] [Abstract][Full Text] [Related]
9. Lineage Switch in an Infant B-Lymphoblastic Leukemia With t(1;11)(p32;q23);
Du J; Chisholm KM; Tsuchiya K; Leger K; Lee BM; Rutledge JC; Paschal CR; Summers C; Xu M
Pediatr Dev Pathol; 2021; 24(4):378-382. PubMed ID: 33749383
[TBL] [Abstract][Full Text] [Related]
10. Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia.
Lin S; Luo RT; Ptasinska A; Kerry J; Assi SA; Wunderlich M; Imamura T; Kaberlein JJ; Rayes A; Althoff MJ; Anastasi J; O'Brien MM; Meetei AR; Milne TA; Bonifer C; Mulloy JC; Thirman MJ
Cancer Cell; 2016 Nov; 30(5):737-749. PubMed ID: 27846391
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometric predictive scoring systems for common fusions ETV6/RUNX1, BCR/ABL1, TCF3/PBX1 and rearrangements of the KMT2A gene, proposed for the initial cytogenetic approach in cases of B-acute lymphoblastic leukemia.
Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Marinakis T; Kostopoulos IV; Stiakaki E; Polychronopoulou S; Paterakis G
Int J Lab Hematol; 2019 Jun; 41(3):364-372. PubMed ID: 30730614
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996.
Piciocchi A; Messina M; Elia L; Vitale A; Soddu S; Testi AM; Chiaretti S; Mancini M; Albano F; Spadano A; Krampera M; Bonifacio M; Cairoli R; Vetro C; Colella F; Ferrara F; Cimino G; Bassan R; Fazi P; Vignetti M
Am J Hematol; 2021 Sep; 96(9):E334-E338. PubMed ID: 34048072
[No Abstract] [Full Text] [Related]
13. Blinatumomab for paediatric mixed phenotype acute leukaemia.
Bartram J; Balasch-Carulla M; Bhojaraja S; Adams S; Cheng D; Inglott S; Kulkarni N; Mahendrayogam A; O'Connor O; Pavasovic V; Vora A
Br J Haematol; 2021 Oct; 195(2):289-292. PubMed ID: 34254287
[No Abstract] [Full Text] [Related]
14. Cryptic recurrent ACIN1-NUTM1 fusions in non-KMT2A-rearranged infant acute lymphoblastic leukemia.
Pincez T; Landry JR; Roussy M; Jouan L; Bilodeau M; Laramée L; Couture F; Sinnett D; Gendron P; Hébert J; Oligny L; Rouette A; Tran TH; Wilhelm BT; Bittencourt H; Cellot S
Genes Chromosomes Cancer; 2020 Feb; 59(2):125-130. PubMed ID: 31515871
[TBL] [Abstract][Full Text] [Related]
15. Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.
Gökbuget N; Zugmaier G; Klinger M; Kufer P; Stelljes M; Viardot A; Horst HA; Neumann S; Brüggemann M; Ottmann OG; Burmeister T; Wessiepe D; Topp MS; Bargou R
Haematologica; 2017 Apr; 102(4):e132-e135. PubMed ID: 28082340
[No Abstract] [Full Text] [Related]
16. Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT.
Esteve J; Giebel S; Labopin M; Czerw T; Wu D; Volin L; Socié G; Yakoub-Agha I; Maertens J; Cornelissen JJ; Pigneux A; Shimoni A; Schwerdtfeger R; Labussière-Wallet H; Russell N; Schattenberg A; Chevallier P; Koza V; Foà R; Schmid C; Peric Z; Mohty M; Nagler A
Leukemia; 2021 Aug; 35(8):2232-2242. PubMed ID: 33542481
[TBL] [Abstract][Full Text] [Related]
17. The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4.
Bursen A; Schwabe K; Rüster B; Henschler R; Ruthardt M; Dingermann T; Marschalek R
Blood; 2010 Apr; 115(17):3570-9. PubMed ID: 20194896
[TBL] [Abstract][Full Text] [Related]
18. Haploidentical peripheral blood stem cell transplantation without irradiation or busulfan after reduced-intensity conditioning for KMT2A(MLL)-rearranged infant B-cell precursor acute lymphoblastic leukemia: Report of two cases.
Yoshimi A; Kato K; Hosaka S; Suzuki R; Fukushima H; Nakao T; Kobayashi C; Fukushima T; Koike K; Sumazaki R; Tsuchida M
Pediatr Transplant; 2017 Jun; 21(4):. PubMed ID: 28332262
[TBL] [Abstract][Full Text] [Related]
19. Mature B-cell acute lymphoblastic leukaemia associated with a rare MLL-FOXO4 fusion gene.
Lim L; Chen KS; Krishnan S; Gole L; Ariffin H
Br J Haematol; 2012 Jun; 157(6):651. PubMed ID: 22429121
[No Abstract] [Full Text] [Related]
20. Durable remissions in
Mouttet B; Vinti L; Ancliff P; Bodmer N; Brethon B; Cario G; Chen-Santel C; Elitzur S; Hazar V; Kunz J; Möricke A; Stein J; Vora A; Yaman Y; Schrappe M; Anak S; Baruche A; Locatelli F; von Stackelberg A; Stanulla M; Bourquin JP
Haematologica; 2019 Jun; 104(6):e244-e247. PubMed ID: 30765470
[No Abstract] [Full Text] [Related]
[Next] [New Search]
